Used in the treatment of osteoporosis, particularly in postmenopausal women at high risk of fracture. It works by inhibiting sclerostin, a protein that suppresses bone formation. By blocking sclerostin, the antibody enhances bone formation and reduces bone resorption, leading to increased bone mineral density and strength. Administered via subcutaneous injection, it has been shown to significantly lower the risk of vertebral and non-vertebral fractures. Treatment duration is typically limited to 12 months due to potential cardiovascular risks with long-term use.